ROIVANT SCIENCES LTD. Gain (Loss) on Disposition of Assets
ROIVANT SCIENCES LTD. (ROIV) reported Gain (Loss) on Disposition of Assets of $110.39 million for the 6-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnDispositionOfAssets1 · last filed 2024-11-12
- ROIVANT SCIENCES LTD. gain (loss) on disposition of assets for the quarter ending 2024-09-30 was $0.00.
- ROIVANT SCIENCES LTD. gain (loss) on disposition of assets for the quarter ending 2024-06-30 was $110.39M.
- ROIVANT SCIENCES LTD. gain (loss) on disposition of assets for the quarter ending 2024-03-31 was $0.00.
- ROIVANT SCIENCES LTD. gain (loss) on disposition of assets for the quarter ending 2023-12-31 was $5.35B.
- ROIVANT SCIENCES LTD. gain (loss) on disposition of assets for fiscal 2024 was $5.35B.
- ROIVANT SCIENCES LTD. gain (loss) on disposition of assets for fiscal 2023 was $0.00.
| Period end | Gain (Loss) on Disposition of Assets 3 month | Gain (Loss) on Disposition of Assets 6 month | Gain (Loss) on Disposition of Assets 9 month | Gain (Loss) on Disposition of Assets 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-12 | $110.39M 10-Q · filed 2024-11-12 | $110.39M derived: sum of 3 quarters · filed 2024-11-12 | $5.46B derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | $110.39M 10-Q · filed 2024-08-09 | $110.39M derived: sum of 2 quarters · filed 2024-08-09 | $5.46B derived: sum of 3 quarters · filed 2024-08-09 | $5.46B derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-30 | $5.35B derived: sum of 2 quarters · filed 2024-05-30 | $5.35B derived: sum of 3 quarters · filed 2024-11-12 | $5.35B 10-K · filed 2024-05-30 |
| 2023-12-31 | $5.35B derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-13 | $5.35B derived: sum of 2 quarters · filed 2024-11-12 | $5.35B 10-Q · filed 2024-02-13 | $5.35B derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-09-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-09 | $0.00 derived: sum of 2 quarters · filed 2024-08-09 | ||
| 2023-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-30 | $0.00 10-K · filed 2024-05-30 | ||
| 2022-12-31 | $0.00 10-Q · filed 2024-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |